Rituximab + Standard CHOP (R･S-CHOP) vs Rituximab+ bi-Weekly CHOP (R･Bi-CHOP) RCT(Phase II/III) for Stage III/IV Low-Grade B-Cell Lymphoma (LowBNHL-RS/BiCHOP-P2/3) (JCOG0203)
Since currently there is no standard therapy for untreated advanced-stage low-grade B-cell
lymphoma, Phase 2/3 study was planned.
Comparison(s): An intensified bi-weekly version by shortening the intervals of
both rituximab and CHOP therapies using G-CSF, compared to the tri-weekly R-CHOP regimen.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
CR rate (phase II)
during the study conduct
Kensei Tobinai, M.D.,Ph.D.
National Cancer Center Hospital
Japan: Ministry of Health, Labor and Welfare